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Background:  Separate  assays  are  available  for  diagnosis  and  viral  load  (VL)  monitoring  of HIV-1.  Studies
have  shown  that using  a single  test  for both  conﬁrmatory  diagnosis  and  VL  increases  linkage  to care.
Objective:  To  validate  a single  assay  for  both  diagnosis  and  VL  monitoring  of  HIV-1  on  the  fully  automated
Panther  platform.
Study design:  Validate  the assay  by  assessing  speciﬁcity,  sensitivity,  subtype  detection,  seroconversion,
reproducibility  and  linearity.  Also  assess  diagnostic  agreement  with  the  Procleix® Ultrio  EliteTM dis-
criminatory  assay  (Procleix),  and  agreement  of  VL  results  (method  comparison)  with  Ampliprep/COBAS
TaqMan  HIV-1  version  2.0  (CAP/CTM),  using  clinical  samples.
Results:  The  assay  was  speciﬁc  (100%)  and sensitive  with  a 95% limit  of detection  of 12 copies/mL  with the
3rd  WHO  standards.  Aptima  detected  HIV in  seroconversion  panels  6 and  11  days  before  p24 antigen  and
antibody  tests,  respectively.  Diagnostic  agreement  with  Procleix,  was  100%.  Regression  analysis  showed
good  agreement  of  VL results  between  Aptima  and  CAP/CTM  with  a slope  of  1.02, intercept  of 0.07,  and
correlation  coefﬁcient  (R2) of 0.97.  Aptima  was  more  sensitive  than  CAP/CTM.  Equivalent  quantiﬁcation
was seen  on testing  clinical  samples  and  isolates  belonging  to  HIV  group  M, N, O  and  P  and  commercially
2available  subtype  panels.  Assay  results  were  linear  (R 0.9994)  with  standard  deviation  of  <0.17  log  copies
across  assay  range.
Conclusions:  The  good  speciﬁcity,  sensitivity,  precision,  subtype  performance  and  clinical  agreement  with
other  assays  demonstrated  by  Aptima  combined  with  the  complete  automation  provided  by  the  Panther
platform  makes  Aptima  a good  candidate  for both  VL  monitoring  and  diagnosis  of HIV-1.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Background
Early diagnosis of HIV-1 infection and linkage to care is essential
n controlling the HIV epidemic because people with acute infec-
ions account for 30–50% of new HIV infections globally [3]. WHO
uidelines [40,41] recommend baseline viral load at the time of
iagnosis in order to improve linkage to care, and the use of viral
oad (VL) monitoring as the preferred approach (compared with
Abbreviations: Aptima, Aptima HIV-1 Quant Dx Assay; VL, viral load; CAP/CTM,
OBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test v2.0; Abbott RT, Abbott RealTime
IV-1 Assay; Procleix, Procleix® Ultrio EliteTM discriminatory assay; LOD, limit of
etection; LOQ, limit of quantiﬁcation; LLOQ, lower limit of quantiﬁcation; ART, anti
etroviral therapy; NAAT, nucleic acid ampliﬁcation test; SD, standard deviation.
∗ Corresponding author.
E-mail address: sangeetha.nair@hologic.com (S.V. Nair).
ttp://dx.doi.org/10.1016/j.jcv.2016.02.002
386-6532/© 2016 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
immunological and clinical monitoring) to provide an early and
more accurate indication of treatment failure. Also, reducing com-
munity viral load through early treatment and monitoring has been
shown to reduce transmission [24].
Detection and quantiﬁcation of HIV-1 is important for diag-
nosis of HIV-1 infections and management of HIV-1 patients
[23,4,11,25,30]. It is also useful for research applications ranging
from studies on viral dynamics [31,39], to investigation of viral
reservoirs [6], community VL [24] and vaccine efﬁcacy studies [27].
Separate assays are currently available for the diagnosis and VL
monitoring of HIV-1. The Aptima HIV-1 Quant Dx Assay (Aptima) is
the ﬁrst commercially available automated nucleic acid test (NAAT)
that has CE certiﬁcation for both diagnosis* and VL monitoring of
HIV-1. The dual claim of Aptima enables clinicians to not only con-
ﬁrm diagnosis of HIV-1 but also simultaneously obtain the patient’s
baseline VL immediately using a single Aptima test without an addi-
tional return visit. Studies have shown that the ability to obtain both
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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 conﬁrmed diagnosis and baseline VL at the same time – ‘single
taging’ – improves linkage to care [2].
. Objective
To evaluate the performance characteristics of Aptima that are
ritical for diagnosis and VL monitoring. This includes evaluation of
peciﬁcity, sensitivity, detection of HIV in seroconversion panels,
quivalent detection of all HIV-1 groups and subtypes, linearity,
recision and l agreement of results of clinical specimens with other
ssays.
. Study design
The Aptima assay runs on the fully automated Panther platform
nd uses speciﬁc target capture, transcription mediated ampliﬁ-
ation and real time detection technologies to achieve the high
ensitivity and broad dynamic range needed for diagnosis and VL
onitoring. This assay targets the highly conserved pol and LTR
egions of HIV in line with other HIV-1 NAATs developed by Hologic
formerly Gen-Probe) such as Aptima HIV-1 RNA Qualitative assay
28,32] Procleix HIV-1/HCV [13,18] and Procleix Ultrio [20]. The
ultiple primers used in this product amplify HIV-1 groups M,  N,
 and P along with an internal control.
.1. Speciﬁcity
A total of 240 fresh and 1020 frozen plasma and serum samples
rocured from Bocabiolistics LLC (48521 West Hillsboro Boulevard,
oconut Creek, CL 33073) in primary blood collection tubes were
ested across 3 Aptima reagent lots using 5 different Panthers.
.2. LOD and LOQ
LOD (limit of detection) and LOQ (limit of quantiﬁcation) studies
ere performed as recommended in the CLSI EP17-A2 guideline.
OD was determined using the 3rd HIV-1 WHO  standard (NIBSC
ode 10/152 Group M,  Subtype B, National Institute for Biological
tandards and Control, Potters Bar, Hertfordshire, EN6 3QG, UK)
iluted to 13 concentrations ranging from 0 to 750 IU/mL using
ooled HIV-1 negative K3 EDTA human plasma (Bocabiolistics).
hirty replicates of each panel member was tested with each of
he 3 lots of Aptima reagents using 3 Panthers.
To determine LOD of subtypes, panels were made by spiking
ooled HIV-1 negative human plasma (Bocabiolistics) with natu-
ally infected clinical specimens belonging to the Group M subtypes
f HIV (A, C, D, F, G, CRF01 AE and CRF02 AG) procured from Dis-
overy Life Sciences (1236 Los Osos Valley Rd., Suite T, Los Osos,
A 93402) and Bocabiolistics. Clinical isolates procured from the
ational Institute of Health AIDS reagents program were used to
ake panels for Group O (BCF-13) and N (YBF-30). These sam-
les were assigned concentrations by testing them in the Roche
OBAS Ampliprep/COBAS TaqMan HIV-1 version 2.0 (CAP/CTM)
nd Abbott RealTime (Abbott RT) HIV-1 assays and averaging the
esults. Six concentration levels from 2 to 40 copies/mL were pre-
ared for each subtype/group and tested on multiple Panthers using
 reagent lots for a total of 60 replicates per concentration. Probit
nalysis was performed using SAS statistical software and the high-
st LOD for each subtype/group between reagent lots was reported
s the LOD of that subtype.
The WHO  standard data used to assess LOD was also used to
etermine the lower limit of quantiﬁcation (LLOQ) of Aptima. LLOQ
as established using the Westgard model presented in CLSI EP17-
2 guideline with acceptable total error set to 1 log copy/mL. Five
oncentrations from 10 to 40 copies/mL were tested at 30 repli- Virology 77 (2016) 46–54 47
cates per panel member with 1 lot of Aptima reagents on multiple
Panthers for conﬁrmation of LLOQ for each subtype/group.
3.3. WHO  LOD comparison with CAP/CTM
WHO  panels with concentrations of 0, 10, 25, 50, 100 and
250 IU/mL, used for assessing LOD of Aptima, were tested with 15
replicates per panel member in CAP/CTM to compare hit rates.
3.4. Seroconversion
HIV-1 seroconversion panel sets (with total 204 panel mem-
bers), collected from 19 different donors were procured from
Zeptometrix (Zeptometrix Corporation 872 Main Street, Buffalo, NY
14202) and Seracare (Seracare Life Sciences, 25 Birch Street, Mil-
ford, MA  01757). Each seroconversion panel set was composed of
7–22 serial specimens collected from a single donor. These were
tested on two  Panthers using one lot of Aptima reagents. Detection
was compared to p24 antigen (Coulter HIV-1 p24 Ag or BioMerieux
p24 Ag test) and HIV-1 antibody (Abbott Anti-HIV 1/2 or Siemens
Anti-HIV 1/2 test) test results provided by Zeptometrix and Ser-
acare. The number of days HIV-1 was  detected with Aptima prior
to detection by the other assays was  assessed.
3.5. Diagnostic agreement with Procleix
A total of 214 HIV positive and 200 negative specimens were
tested in Aptima across 2 reagent lots and 3 Panthers. A second
aliquot of the same sample was tested in the Procleix® Ultrio EliteTM
HIV Discriminatory Assay (Hologic, Inc.).
3.6. Diagnostic agreement and method comparison with
CAP/CTM
A method comparison between Aptima and CAP/CTM assays
was performed by testing 881 fresh and 346 frozen clinical
specimens in both assays. The frozen specimens, procured from
Discovery Life Sciences, Bocabiolistics and Seracare were selected
based on subtype (subtype A, B, C, D, F, G, H, CRF01 AE, CRF02 AG,
CRF39 BF CRF47 BF, CRF14 BG, other recombinants and URFs) and
region of origin (includes specimens from Europe, Africa, North
America, South America and Asia). Cerba Specimen Services, France
prospectively collected the fresh specimens with approval of their
institutional review board. All specimens were thawed at room
temperature, centrifuged at 1100 RCF for 10 min  at 4 ◦C and tested
in both assays. All results were used to assess diagnostic agree-
ment between CAP/CTM and Aptima. For method comparison the
results of only 342 frozen and 108 fresh specimens that gave quan-
tiﬁable results in both assays was used to perform linear regression
and Bland Altman analysis, using ANALYZE-IT software. The ﬁtted
regression line was  compared to the line of equality by testing
the two-tailed hypothesis of slope = 1 and intercept = 0 to assess
agreement and bias between the two assays.
3.7. Additional testing on HIV-1 groups, subtypes and
recombinants
The Seracare worldwide performance panel, NIBSC subtype
panel 12/224, 16 Group O clinical samples from Cameroon, Africa
(Sileagen, Austin Tx), as well as panels of 13 HIV Group O, 1 Group N
(NIH AIDs Reagents Program) and 1 Group P clinical isolate target-
ing log 4 copies/mL were tested in Aptima, CAP/CTM and/or Abbott
RT assays.
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Table 1
Predicted 95% detection Limits (LOD) and lower limit of quantitation (LLOQ) for
HIV-1 Groups and Subtypes.
Subtype/group 95% LOD (copies/mL)a LLOQ in copies/mL
A 12.3 30
B  (NIBSC standard) 12.1 15
CRF01 AE 6.2 10
CRF02 AG 15.4 30
C  10.7 30
D  14.0 15
F  8.3 15
G  17.5 30
N  7.8 10
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Table 2
Comparison of sensitivity (% reactivity) of Aptima and CAP/CTM using the same 3rd
WHO  standard dilutions.
NIBSC 3rd standard IU/mL % Reactivity in Aptima* % Reactivity in CAP/CTM
0 0% 0%
10 67% 53%
25 90% 60%
50 100% 80%
100 100% 100%
250 100% 100%
Table 3
Comparison of HIV detection between Aptima and CAP/CTM.
CAP/CTM
TND DetectedO  8.0 15
a IU/mL multiplied with the Conversion factor of 0.35 copies/IU.
.8. Linearity
The linear range of Aptima was established by testing panels
hat consisted of cultured HIV-1 subtype B virus (Seracare) diluted
n HIV-1 negative human plasma (Seracare) according to CLSI EP6-
2. The 11 panels ranged in concentration from 1.30 to 7.30 log
opies/mL and were tested with a total of 60 replicates per concen-
ration with 2 Aptima reagent lots across 7 Panthers.
The linearity of Aptima results across group M (subtypes A, B, C,
, F, G, H, CRF01 AE) N and O was conﬁrmed by testing 6 concentra-
ion levels ranging from 2.00 to 6.50 log copies/mL of each HIV-1
ranscript. Transcripts were diluted in Aptima Specimen Diluent
Hologic, Inc. San Diego CA) and tested with 20 replicates per con-
entration with 1 reagent lot. The concentration of the transcript
tocks were determined by calculation using the optical density
alue from spectrophometry.
.9. Precision
The reproducibility of Aptima was assessed by testing one nega-
ive and 8 HIV-1 positive panels using 3 reagent lots and 3 operators
n 59 runs with 3 replicates per run (total 162 replicates per panel)
n 3 panthers over a period of 20 days. Panels were manufactured
y spiking HIV-1 subtype B (Seracare) into HIV negative plasma
Seracare) at concentrations targeting 1.7 to 6.7 copies/mL. One
anel was diluted 1:3 (240 L specimen added to 480 L specimen
iluent available from Hologic, Inc.) and tested on Panther using its
utomated dilution function. The results of valid quantiﬁable repli-
ates of the HIV-1 panels was analyzed using SAS statistics program
or assessment of precision.
. Results
The speciﬁcity of the Aptima assay was 100% on testing fresh
nd frozen plasma and serum specimens from HIV-1 negative blood
onors (Table A in Supplement).
The highest 95% LOD with WHO  standards (group M subtype
) across the 3 reagent lots was calculated to be 12.1 copies/mL
35 IU/mL; 0.35 copies = 1 IU) using probit analysis as seen from
able 1. The highest 95% LOD among subtypes on testing with 2
eagent lots was 17.5 copies/mL (Table 1).
The highest LLOQ determined through testing of dilutions of
he 3rd WHO  standard across three reagent lots was  15 copies/mL.
owever, LLOQ for the assay was set at 30 copies/mL because the
LOQ of subtypes A, C, G and CRF02-AG were 30 copies/mL.
Aptima had a higher detection rate than CAP/CTM when the
ame sensitivity panel made from the 3rd WHO  standard was tested
n both assays (Table 2).
The same trend of higher detection rate was seen with Aptima
ompared to CAP/CTM when testing clinical specimens from HIV
ositive patients on ART for the method comparison study (Table 3).Aptima HIV-1 Quant Dx Assay TND 326 78
Detected 204 619
Aptima detected HIV-1 in 204 of the 1227 specimens (17%) that
were not detected by CAP/CTM while CAP/CTM was able to detect
HIV in 78 specimens (6%) which were not detected in Aptima.
Among the 204 specimens detected by Aptima but not CAP/CTM
only 11 (0.9% of total specimens) reported quantitative results (>30
copies/mL LLOQ) with the highest viral load reported among these
specimens being 85 copies/mL. For the 78 specimens detected by
CAP/CTM but not Aptima the highest viral load among these speci-
mens was  79 copies/mL. For the remaining 945 specimens (77%)
the results were concordant in both assays. Agreement of 100%
was seen in the diagnostic results between the Aptima and Procleix
(Table B in Supplement).
On testing seroconversion panels an average reduction in win-
dow period of 5.6 days and 11.2 days was  observed on testing with
Aptima compared with p24 antigen and antibody test respectively
(Table 4).
Linear regression analysis, performed with the results of 450
specimens that gave quantiﬁable results in both Aptima and
CAP/CTM had a slope of 1.02 (95% conﬁdence interval 1.000–1.047),
intercept of 0.07 (95% conﬁdence interval −0.0223 to 0.1646), and
correlation coefﬁcient of 0.97 (Fig. 1). The results of 86% of the spec-
imens with quantiﬁable results in both assays were within 0.5 logs
of each other with only two specimens differing by more than 1
log between the 2 assays. Abbott results were within 0.56 logs of
Aptima results for both these specimens. The Aptima, CAP/CTM,
and Abbott results were 4.01, 2.68, and 3.59 log copies/mL for the
ﬁrst specimen and 1.83, 2.89 and 2.39 log copies/mL for the sec-
ond specimen. Aptima results were on average 0.16 log higher than
CAP/CTM on Bland Altman analysis (Fig. 2).
On testing the Seracare Worldwide HIV Performance Panel com-
posed of subtypes and rare recombinants of Group M,  Aptima
results were on average within 0.21 log of CAP/CTM (Table 5). For
the NIBSC subtype panel, Aptima results were on average within
0.15 log of the CAP/CTM and 0.34 log of Abbott RT results (Table 5).
For Group N sample, the Aptima and CAP/CTM results were within
0.08 log of each other but the Abbott RT result was more than one
log lower than both the Aptima and CAP/CTM results (Table 5). On
testing clinical samples and cell culture isolates belonging to HIV-1
Group O, Aptima results were within 1 log of either the CAP/CTM
or Abbott RT results (Table 5). For Group N and P clinical isolates
the Aptima result was  within 0.68 log of the CAP/CTM results but
the Abbott RT results were 1.09 and 1.22 log lower than the Aptima
results.Fig. 3 demonstrates the linearity of the Aptima assay with an
R2 value of 0.9994 across a concentration range from 1.3 to 7.3 log
copies/mL. The concentration range within which the Aptima assay
reports quantitative results (1.47–7 log copies/mL) is well within
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Table  4
Comparison of window period on testing HIV-1 seroconversion panels with the Aptima assay versus Antibody (Ab) and Antigen (Ag) tests.
Panel ID Number of panel
members in the set
Days to ﬁrst reactive result Difference in days to ﬁrst reactive
result (based on bleed date)
Aptima HIV-1 Quant Dx HIV p24 Antigen Anti-HIV 1/2 Antibody Days earlier
detection than
HIV  p24 Antigen
Days earlier detection
than Anti-HIV 1/2
Antibody
Set 1 7 14 18 25 4 11
Set  2 10 18 25 32 7 14
Set  3 9 21 21 30 0 9
Set  4 10 27 30 34 3 7
Set  5 11 21 28 32 7 11
Set  6 22 83 87 97 4 14
Set  7 17 43 47 57 4 14
Set  8 9 23 25 32 2 9
Set  9 22 71 78 85 7 14
Set  10 16 40 47 54 7 14
Set  11 13 41 46 53 5 12
Set  12 6 7 16 20 9 13
Set  13 13 21 28 33 7 12
Set  14 6 7 14 17 7 10
Set  15 7 9 17 21 8 12
Set  16 10 35 44 48 9 13
Set  17 4 7 9 16 2 9
Set  18 5 7 14 14 7 7
Set  19 7 26 33 33 7 7
Total  204 Mean 5.58 11.16
Median 7 12
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oFig. 1. Linear regression between quanti
he linear range of the assay. Acceptable linearity was observed
cross this quantiﬁcation range for all subtypes/Groups of HIV-1
ith the lowest R2 value among all subtypes being 0.9993 (Fig. 4)
As can be seen from Table 6 the Aptima assay had ≤0.17 stan-
ard deviation (SD) log copies variability across the assay range.
t the concentration close to 60 copies/mL (1.8 log copies/mL),
ptima exhibited good precision with 0.16 SD log copy. Even the
00 copies/mL specimen that was diluted 1:3 with specimen dilu-
nt prior to testing had a total variability of 0.15 SD log copy. The
ariability between reagent lots, Panthers, operators and runs were
inimal with intra run variability being the highest contributor to
he total variability.
. DiscussionTo improve detection of acute infections, which accounts for
0–50% of transmissions [3], the Center for Disease Control and
thers has recommended the addition of NAATs to HIV diagnosticsults for HIV-1 in Aptima and CAP/CTM.
algorithms for conﬁrmation of infection [5,32]. The high speciﬁcity
and sensitivity (Tables 1–3 and Table A in Supplement) of Aptima,
earlier detection of HIV-1 in seroconversion panels (Table 4), diag-
nostic performance in par with a blood screening assay (Table
B in Supplement), as well as the complete automation and high
throughput provided by the Panther system makes Aptima an
attractive option for use in HIV diagnostic algorithms to prevent
transmission. Because Aptima has CE certiﬁcation for both diagno-
sis and VL monitoring, a single test in this assay can be used for
both conﬁrmatory diagnosis and VL monitoring of HIV-1, shorten-
ing time for linkage to care. Linkage to care is vital to control the
global HIV epidemic [8,42].
Assays that quantify the various HIV subtypes and recombinants
with equal efﬁciency and accuracy are required for effective clinical
management of patients on ART [35,36,37,38]. Good agreement of
VL results were seen in a method comparison between Aptima and
CAP/CTM (Fig. 1) with only 2 out of 450 samples (0.44%) report-
ing results that differed by greater than 1 log. In both these cases
50
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Table 5
Results of SeraCare Worldwide HIV Performance Panel, NIBSC 12/224 panels and Group O, N and P samples in Aptima, CAP/CTM and Abbott RT assays.
Sample ID Origin of sample Groups (isolate ID) Aptima Result (log
copies/mL)
CAP/CTM Result (log
copies/mL)
Abbott RT  Result (log
copies/mL)
Absolute difference
between Aptima and
CAP/CTM
Absolute difference
between Aptima and
Abbott RT
Absolute difference
between CAP/CTM and
Abbott RT
WWRB305-01 Krygyzstan A 4.62 4.72 Not Available 0.10 Not applicable Not  applicable
WWRB305-02 Honduras B 4.24 4.41 0.17
WWRB305-03 Ecuador B 5.17 5.23 0.06
WWRB305-04 South Africa C 3.37 3.52 0.15
WWRB305-05 Not available C 3.84 4.00 0.16
WWRB305-06 Germany CRF01 AE 4.48 4.86 0.38
WWRB305-07 Krygyzstan CRF01 AE 5.59 5.04 0.54
WWRB305-08 Nigeria CRF02 AG 2.78 2.64 0.13
WWRB305-09 Ecuador CRF02 AG 5.30 5.08 0.22
WWRB305-10 Krygyzstan CRF02 AG 4.71 4.72 0.01
WWRB305-11 Germany CRF03 AB 4.31 4.34 0.03
WWRB305-12 Krygyzstan CRF03 AB 3.23 3.04 0.19
WWRB305-13 Germany D 4.34 4.52 0.17
WWRB305-14 Germany D 3.79 4.11 0.33
WWRB305-15 Germany G 4.60 4.64 0.04
WWRB305-16 Ivory Coast K 3.93 4.18 0.25
WWRB305-17 Congo H/A1 3.03 3.08 0.05
WWRB305-18 Congo K/CRF09 2.57 2.73 0.16
WWRB305-19 Congo G/CRF02 3.52 4.30 0.78
WWRB305-20 Thailand CRF01/CRF15 4.61 4.95 0.34
Average difference for Seracare Panel 0.21
11/150 Uganda A (92UG037) 3.65 3.61 3.28 0.04 0.37 0.33
11/152 Thailand B (92TH014) 3.44 3.66 3.32 0.22 0.12 0.34
11/154 Tanzania C (98TZ017) 3.61 3.84 3.23 0.23 0.38 0.61
11/156 Uganda D (94UG114) 3.41 3.59 3.15 0.18 0.26 0.44
11/158 Thailand A/E (92TH001) 3.34 3.64 3.22 0.30 0.12 0.42
11/160 Brazil F (93BR020) 3.78 3.79 3.45 0.01 0.33 0.34
11/162 Russia G (RU570) 3.75 3.97 3.60 0.22 0.15 0.37
11/164 Gabon AG/GH (VI525) 3.97 3.90 3.76 0.07 0.21 0.14
11/166 Cameroon N (YBF30) 3.50 3.42 2.15 0.08 1.35 1.27
11/168 Cameroon O (MVP5180) 3.35 3.18 3.27 0.17 0.08 0.09
Average difference for NIBSC panel 0.15 0.34 0.44
Clinical sample 1 Cameroon O 4.93 4.49 4.72 0.44 0.21 0.23
Clinical sample 2 Cameroon O 2.67 2.28 2.41 0.39 0.26 0.13
Clinical sample 3 Cameroon O 2.96 2.56 2.57 0.40 0.39 0.01
Clinical sample 4 Cameroon O 4.72 4.47 3.23 0.25 1.49 1.24
Clinical sample 5 Cameroon O 4.82 4.60 4.28 0.22 0.54 0.32
Clinical sample 6 Cameroon O 4.95 4.65 4.41 0.30 0.54 0.24
Clinical sample 7 Cameroon O 4.98 4.01 3.53 0.97 1.45 0.48
Clinical sample 8 Cameroon O 4.64 4.32 4.10 0.32 0.54 0.22
Clinical sample 9 Cameroon O 4.33 4.45 3.85 0.12 0.48 0.60
Clinical sample 10 Cameroon O 3.35 3.05 2.69 0.30 0.66 0.36
Clinical sample 11 Cameroon O 3.70 3.06 3.91 0.64 0.21 0.85
Clinical sample 12 Cameroon O 2.93 4.47 3.42 1.54 0.49 1.05
Clinical sample 13 Cameroon O 3.96 2.73 3.15 1.23 0.81 0.42
Clinical sample 14 Cameroon O 5.36 4.33 Repeat invalid 1.03 Not applicable Not  applicable
Clinical sample 15 Cameroon O 3.87 3.54 2.71 0.33 1.16 0.83
Clinical sample 16 Not available O 3.52 3.93 Not available 0.41 Not applicable Not  applicable
Clinical isolate 1 Cameroon O (BCF01) 4.34 4.02 3.90 0.32 0.44 0.12
Clinical isolate 2 Cameroon O (BCF02) 3.96 3.66 4.00 0.30 0.04 0.34
Clinical isolate 3 Cameroon O (BCF03) 3.73 3.85 3.94 0.12 0.21 0.09
Clinical isolate 4 Cameroon O (BCF06) 3.89 4.15 4.20 0.26 0.31 0.05
Clinical isolate 5 Cameroon O (BCF07) 3.54 2.92 4.04 0.62 0.50 1.12
Clinical isolate 6 Cameroon O (BCF11) 4.37 4.15 4.31 0.22 0.06 0.16
Clinical isolate 7 Cameroon O (BCF13) 4.43 3.12 4.28 1.31 0.15 1.16
Clinical isolate 8 Cameroon O (CA9W) 3.66 3.54 3.40 0.12 0.26 0.14
Clinical isolate 9 Cameroon O (MVP5180) 3.65 3.25 3.73 0.40 0.08 0.48
Clinical isolate 10 (USA) O(I-2478B) 5.18 4.81 4.80 0.37 0.38 0.01
Clinical isolate 11 Spain O (I-2481) 5.45 4.56 5.22 0.89 0.23 0.66
Clinical isolate 12 Cameroon N (YBF-30) 3.67 3.14 2.45 0.53 1.22 0.69
Clinical isolate 13 France P (RBF-168) 3.76 3.08 2.67 0.68 1.09 0.41
Average difference for Group O, N and P 0.52 0.53 0.46
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Fig. 2. Bland Altman analysis of Aptima and CAP/CTM results.
Fig. 3. Linear range of the Aptima Assay established with dilutions of HIV-1.
Table 6
Reproducibility across the range of the Aptima assay.
Number of valid quantiﬁable replicatesa Mean Concentration (log copies/mL) Inter-instrument Inter-operator Inter-lot Inter-run Intra-run Total
SDc SD SD SD SD SD
137 1.80 0.00 0.03 0.00 0.00 0.16 0.16
157  2.37 0.00 0.05 0.01 0.08 0.15 0.17
160  2.47b 0.00 0.03 0.03 0.07 0.12 0.15
162  2.95 0.00 0.08 0.02 0.10 0.09 0.15
162  3.80 0.01 0.03 0.02 0.06 0.07 0.10
159  4.93 0.00 0.02 0.04 0.05 0.04 0.08
162  5.69 0.00 0.02 0.04 0.03 0.07 0.09
162  6.71 0.00 0.01 0.04 0.04 0.05 0.08
a Out of 1296 reactions tested results of 35 replicates were excluded from analysis. Of these 27 were excluded because they were below LLOQ, 3 were chemistry invalids
and  5 were invalid because there was not enough sample volume in the tube.
b Panel member was diluted 1:3 just prior to run. Reported result (shown here) has dilution factor of 3 applied automatically by the Panther system.
c SD = standard deviation.
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ptima results were within 0.56 log of the Abbott RT results. This
s a high level of agreement considering the fact that this study
ncluded specimens belonging to various rare recombinants and
ubtypes of HIV-1 collected from different geographic locations
ncluding Europe, Africa, North America, South America and Asia.
he level of agreement between Aptima and CAP/CTM seen in this
tudy was equivalent or better than those reported in comparison
tudies between other HIV VL assays [1,12,33,14,35,36,37]. Others
ave also demonstrated comparable results between Aptima and
bbott RT, CAP/CTM, Qiagen Artus HI Virus-1 QS-RGQ, NucliSens
asy Qv2.0 and Xpert [10,17,19,22,26,29,34].
Results of additional testing conducted with Seracare World-
ide HIV performance panel and WHO/NIBSC subtype panel also
how good agreement between Aptima results and that of assays
uch as CAP/CTM and Abbott RT (Table 5). Aptima results were
ithin 0.5 log of either the CAP/CTM or Abbott RT results for 27
f the 29 clinical specimens and isolates belonging to highly diver-
ent Group O (Table 5) and within 1 log for samples belonging to
roup N and P. This demonstrates that in spite of the sequence
ariability between the various groups of HIV-1, Aptima is able to
ccurately detect and quantify HIV-1 belonging to all these groups
nd subtypes. Other investigators have also demonstrated equiva-
ent subtype detection with Aptima by testing HIV-1 subtype panels
rom the Institute of Virology, University of Erlangen, Germany, CAP
014, Qnostics, INSTAND and Seracare [26,34]. Ehret and colleagues
lso demonstrated accurate quantiﬁcation of Aptima with a panel
f integrase inhibitor drug resistance mutants [10].
Multiple studies have assessed the impact of low level viremia
ith long term clinical outcomes such as frequency of oppor-
unistic infections and probability of maintaining viral suppression
7,9,15,21]. Persistently detectable low level viremia may  predict
ubsequent virologic failure and development of drug resistance
utations [15,21]. Table 3 shows that the high sensitivity of Aptima
nabled the assay to detect HIV in 204 specimens from HIV patients
n ART with “Not Detected” results in CAP/CTM while CAP/CTM
etected HIV in only 78 samples with “Not Detected” results in
ptima. Among the 204 specimens detected by Aptima only 7 had
 viral load above 50 copies/mL (highest result was  85 copies/mL).d Groups in the Aptima assay.
All these values were under the 200 copies/mL threshold that trig-
gers evaluation of treatment change as per the recommendation in
the DHHS guidelines and were performed in singlet (not consecu-
tive viral loads) [30]. Persistent low level viremia under 100 copies
may  be indicative of potential viral breakthrough or even adher-
ence issues. Given the era of increasing HIV resistance, having an
ultrasensitive assay to detect persistent low level viremia may be
critical in preserving 2nd line treatments and maintaining posi-
tive clinical outcomes. Additionally, as HIV treatments improve in
efﬁcacy, driving viral load concentrations as low as possible with
the most sensitive assay may  prove to be the preferred route to
truly reducing transmission of HIV [8]. And, a sensitive and precise
assay is also required to monitor VL of untreated elite controller
patients who  have low VL [16] and those enrolled in vaccine trials
[27] to ensure the lowest viral loads possible. The high sensitivity
(Tables 1–3) and precision (Table 6) of Aptima may make it useful
for studies that involve monitoring low level viremia.
The Aptima assay runs on the fully automated Panther sys-
tem, reducing demands for skilled operators and the possibility of
human error. The system provides HIV-1 results from clinical sam-
ples in primary blood collection tubes (K2 EDTA, K3 EDTA, ACD, PPT,
serum tubes and SST) that are directly loaded on to the Panther after
centrifugation preventing the need for manual transfers [26,35]. In
a workﬂow analysis between Aptima and Abbott RT with a sample
size of 96, the authors reported a 70% reduction hand-on-time com-
pared to Abbott m2000 reducing the burden on human resources
[10]. While Aptima has comparable performance to other assays
approved for VL monitoring, the CE certiﬁcation for diagnosis for
this assay enables using a single assay for both diagnosis and VL
monitoring, thereby improving linkage to care by reducing loss to
follow-up. Use of a single test also reduces costs incurred when
running separate tests for conﬁrmation of infection and generation
of VL result. The complete automation, particularly random access
and ease of use provided by the Panther system, in combination
with the good performance of the Aptima [43] makes this assay
a suitable option for any clinical laboratory seeking ﬂexibility in
batch sizes without as much reagent wastage as other automated
platforms.
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